DAI-PP Consortium
Advanced cardiac research
The DAI-PP consortium, founded in 2012, brings together French research efforts in the field of implantable cardioverter-defibrillators. Since 2018, it has developed a large prospective cohort of 10,000 patients implanted for primary or secondary prevention, followed in real time over 10 years through structured remote monitoring, under the sponsorship of Inserm. The consortium has since expanded its scope to encompass all cardiac rhythm management devices and coordinates multiple national multicenter observational and interventional studies within a structured governance framework that ensures coherent and collaborative scientific output.
DAI-PP
Défibrillateur Automatique Implantable – Prévention Primaire
HONEST
The coHOrte fraNcaise des dEfibrillateurs Sous cuTanés
FOREVER
French cOhoRte Extra-Vascular implantable cardiovErter defibrillatoR
DAI-T4F
Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator: The DAI-T4F Nationwide Registry
AV-CESAR
micra AV french Cohort Evaluating the effectiveneSs of Atrioventricular synchRony
PROFID
PRevention Of sudden cardiac death aFter myocardial Infarction by Defibrillator implantation
ALLEGRO
reAL-world evaLuation of carE trajectories and lonG-term outcomes in patients with aRrhythmias in the french natiOnwide database
Upcoming Event
Join us at our next major event in cardiovascular research
Investigators Meeting Consortium DAI-PP
Dining cocktail the night before.
Our Research Focus
We combine innovative methodologies with clinical expertise to drive breakthrough discoveries in cardiovascular medicine and improve patient outcomes worldwide.
Sudden Cardiac Death Prediction
Developing advanced risk stratification models and predictive algorithms to identify patients at high risk of sudden cardiac death, enabling timely preventive interventions.
New Technologies for Cardiac Prevention
Evaluating cutting-edge implantable devices, remote monitoring systems, and AI-powered diagnostic tools to revolutionize cardiac arrhythmia prevention and management.